Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation

Affiliations

¹ Dr Tatjana Potpara, MD, PhD, FESC, Cardiology Clinic, Clinical Center of Serbia, Visegradska 26, 11000 Belgrade, Serbia, Tel: +381 11 3616319, Fax: +381 11 3616319, E-mail: tanjapotpara@gmail.com;, tatjana.potpara@mfub.bg.ac.rs.

Editorial

Tatjana S Potpara. Thromb Haemost. 2015.

. 2015 Nov 25;114(6):1093-8.

doi: 10.1160/TH15-10-0825. Epub 2015 Nov 12.

¹ Dr Tatjana Potpara, MD, PhD, FESC, Cardiology Clinic, Clinical Center of Serbia, Visegradska 26, 11000 Belgrade, Serbia, Tel: +381 11 3616319, Fax: +381 11 3616319, E-mail: tanjapotpara@gmail.com;, tatjana.potpara@mfub.bg.ac.rs.

No abstract available

Comment on

A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, Schwartzman E. Villines TC, et al. Thromb Haemost. 2015 Nov 25;114(6):1290-8. doi: 10.1160/TH15-06-0453. Epub 2015 Oct 8. Thromb Haemost. 2015. PMID: 26446456
Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Seeger JD, et al. Thromb Haemost. 2015 Nov 25;114(6):1277-89. doi: 10.1160/TH15-06-0497. Epub 2015 Oct 8. Thromb Haemost. 2015. PMID: 26446507